Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement

Oxford Expression Technologies (OET, Oxford, UK) and Eden Biodesign (Liverpool, UK) have signed a co-marketing agreement. Under the terms of the agreement, OET will offer its customers access to Eden Biodesign’s process development, clinical trial cGMP manufacturing, and analytical development services. In return, Eden Biodesign’s customers will have access to OET’s wide range of baculovirus capabilities to meet their individual protein expression requirements.